What is the five-year mortality rate for each FACED severity category?

From the original Martinez-Garcia cohort: mild (0-2) approximately 3-4%, moderate (3-4) approximately 15-20%, severe (5-7) exceeding 50% in some analyzes. Absolute rates vary across populations and healthcare settings.

Can the FACED score be applied to newly diagnosed patients?

Yes, with the caveat that the chronic Pseudomonas component requires 12 months of microbiological follow-up to assess reliably. Score as 0 for this component in newly diagnosed patients lacking sufficient culture history.

Are there guideline recommendations linked to FACED score categories?

The ERS (2017) and BTS bronchiectasis guidelines recommend validated severity scores including FACED for disease staging and management planning. Specific protocols may vary by institution and national guideline adaptation.

What is the relationship between FACED score and pulmonary rehabilitation?

Pulmonary rehabilitation benefits patients across all FACED severity levels. Those with mMRC grade 2 or higher (D component scoring) have significant functional impairment and should be prioritised for rehabilitation referral.

FACED Score Calculator- Free Bronchiectasis Severity and Mortality Risk Tool

FACED Score Calculator: Predicting Bronchiectasis Severity and Mortality Risk

The FACED score is a validated multivariate clinical scoring tool designed to predict all-cause mortality in patients with non-cystic fibrosis bronchiectasis. Developed from a large multicenter Spanish cohort study, it has since been validated across diverse global populations and serves as one of the most widely used prognostic instruments for this chronic lung condition. By combining five readily available clinical parameters, the FACED score enables clinicians worldwide to stratify disease severity, guide management intensity, and counsel patients about long-term prognosis.

Non-cystic fibrosis bronchiectasis is a chronic respiratory condition characterized by permanent, irreversible dilatation of the bronchi, resulting from repeated cycles of infection and inflammation. It causes significant morbidity through chronic productive cough, recurrent pulmonary exacerbations, progressive decline in lung function, and reduced quality of life. Until the development of validated scoring tools like FACED, bronchiectasis lacked standardised severity classification systems comparable to those available for other chronic lung conditions such as COPD or pulmonary fibrosis.

FACED Score Formula

FACED = FEV1 points + Age points + Chronic colonisation points + Extension points + Dyspnoea points

Component Scoring:
F – FEV1 (% predicted): <50% = 2 points | ≥50% = 0 points
A – Age: ≥70 years = 2 points | <70 years = 0 points
C – Chronic Pseudomonas aeruginosa colonisation: Yes = 1 point | No = 0 points
E – Extension (lobes affected): >2 lobes = 1 point | ≤2 lobes = 0 points
D – Dyspnoea (mMRC scale): Grade ≥2 = 1 point | Grade <2 = 0 points
Total possible score: 0-7 points

Clinical Background and Development of the FACED Score

The FACED score was developed by Martinez-Garcia and colleagues, published in 2014 in the European Respiratory Journal. The derivation cohort comprised 819 patients with non-cystic fibrosis bronchiectasis recruited from seven Spanish hospitals, with an independent validation cohort of 522 patients. The primary endpoint was all-cause mortality over a five-year follow-up period, making it one of the most rigorous prognostic validation studies conducted in this patient population at that time.

The development methodology followed established multivariable logistic regression principles, identifying clinical and functional variables independently associated with mortality after adjustment for confounders. From an initial pool of candidate variables, five parameters emerged as the strongest independent predictors: forced expiratory volume in one second as a percentage of predicted (FEV1%), age, chronic Pseudomonas aeruginosa bronchial colonisation, radiological extension on computed tomography, and dyspnoea severity measured by the modified Medical Research Council scale.

The resulting scoring system demonstrated excellent discriminatory ability in both derivation and validation cohorts, with area under the receiver operating characteristic curve values exceeding 0.80 — a threshold generally considered to indicate good prognostic performance for clinical prediction models. Subsequent independent validation studies conducted in Italy, the United Kingdom, South Korea, Greece, and other countries have confirmed the score’s generalisability across diverse healthcare settings and patient populations.

Understanding Each FACED Score Component

Each of the five components within the FACED score reflects a distinct pathophysiological dimension of bronchiectasis severity, contributing meaningfully to the overall prognostic assessment.

FEV1 (Forced Expiratory Volume in 1 Second): Lung function impairment, measured by FEV1 as a percentage of the predicted value, is one of the strongest predictors of mortality in bronchiectasis. An FEV1 below 50% of predicted reflects severe airflow obstruction and carries the highest point weighting in the FACED score (2 points). This threshold corresponds broadly to the severe impairment category used in spirometric classification, and patients with values below this level face substantially elevated mortality risk regardless of other clinical features.

Age: Age at diagnosis or assessment strongly influences prognosis in bronchiectasis, partly because older patients have reduced physiological reserve, greater comorbidity burden, and less capacity to tolerate recurrent exacerbations. The FACED score uses a dichotomous threshold of 70 years, assigning 2 points to patients aged 70 or older. This age cut-point was empirically derived from the original cohort and reflects the clinical observation that the relationship between age and mortality accelerates markedly after the seventh decade.

Chronic Pseudomonas aeruginosa Colonisation: Chronic bronchial colonisation with Pseudomonas aeruginosa is a particularly adverse prognostic indicator in bronchiectasis. This Gram-negative organism is associated with increased airway inflammation, more frequent and severe exacerbations, accelerated lung function decline, and greater healthcare utilisation. Chronic colonisation is typically defined as repeated isolation of Pseudomonas aeruginosa from sputum culture on three or more occasions over at least twelve months. In the FACED scoring system, confirmed chronic colonisation with this organism adds 1 point to the total score.

Extension (Radiological Involvement): The radiological extent of bronchiectasis on high-resolution computed tomography (HRCT) provides valuable information about disease burden beyond what spirometry alone captures. Involvement of more than two lung lobes reflects more advanced and diffuse disease, with correspondingly greater impact on mucociliary clearance efficiency, infection risk, and functional reserve. HRCT scoring of lobe involvement should be performed systematically, counting the five standard lung lobes individually. More than two affected lobes earns 1 point in the FACED scoring system.

Dyspnoea (Modified MRC Scale): Patient-reported dyspnoea, assessed using the modified Medical Research Council (mMRC) breathlessness scale, captures the functional impact of bronchiectasis on daily activities in a way that spirometry alone cannot. The mMRC scale ranges from grade 0 (breathless only with strenuous exercise) to grade 4 (too breathless to leave the house or breathless when dressing). In the FACED score, an mMRC grade of 2 or higher — indicating breathlessness that limits activity on level ground — scores 1 point and reflects clinically meaningful functional impairment.

Modified MRC (mMRC) Dyspnoea Scale

Grade 0 to Grade 4

Grade 0: Breathless only with strenuous exercise
Grade 1: Short of breath when hurrying on level ground or walking up a slight hill
Grade 2: Walks slower than people of the same age on level ground, or stops for breath after walking about 100 metres (or after a few minutes) on level ground
Grade 3: Stops for breath after walking about 100 metres (or after a few minutes) on level ground
Grade 4: Too breathless to leave the house, or breathless when dressing or undressing

Score ≥2 points = 1 FACED point

FACED Score Interpretation and Severity Categories

The FACED score stratifies bronchiectasis patients into three severity categories based on total points accumulated, each associated with distinct five-year all-cause mortality estimates derived from the original derivation and validation cohorts.

Patients with a FACED score of 0 to 2 are classified as having mild bronchiectasis. This group demonstrated a five-year mortality rate of approximately 3 to 4% in the original study, representing a relatively favorable prognosis that may justify less intensive monitoring schedules and a focus on maintaining current lung function rather than aggressive escalation of treatment.

A FACED score of 3 to 4 defines moderate bronchiectasis. Five-year mortality in this intermediate group ranged from approximately 15 to 20% in the original cohort. These patients warrant closer clinical follow-up, optimization of airway clearance strategies, consideration of long-term macrolide therapy where appropriate, and thorough assessment for treatable contributing factors such as immunodeficiency or allergic bronchopulmonary aspergillosis.

A FACED score of 5 to 7 indicates severe bronchiectasis with the highest mortality risk. Five-year mortality in this category exceeded 50% in some analyzes. These patients require the most intensive management approach, including regular specialist review, pulmonary rehabilitation consideration, optimization of nutritional status, and in selected cases evaluation for advanced therapeutic options including long-term inhaled antibiotics or, exceptionally, lung transplantation assessment.

FACED Score Severity Classification

Score 0-2: Mild | Score 3-4: Moderate | Score 5-7: Severe

Mild (0-2 points): ~3-4% five-year all-cause mortality
Moderate (3-4 points): ~15-20% five-year all-cause mortality
Severe (5-7 points): >50% five-year all-cause mortality (in some cohorts)

Note: Mortality estimates vary across populations and study cohorts. Clinical interpretation should account for individual patient factors, comorbidities, and local disease burden.

The E-FACED Score: An Extended Version

Recognising that exacerbation history is one of the most powerful predictors of future exacerbations and disease progression in bronchiectasis, Martinez-Garcia and colleagues subsequently developed the E-FACED score as an extension of the original tool. The E-FACED score adds one additional parameter: a history of one or more exacerbations in the preceding year, which contributes 2 points to the total score, raising the maximum possible score from 7 to 9 points.

The E-FACED score has shown superior predictive performance for future exacerbations compared to the original FACED score, which was primarily optimized for mortality prediction. For clinicians whose primary concern is anticipating and preventing exacerbation burden — and the associated hospitalisations, antibiotic courses, and quality-of-life impairment — the E-FACED score may provide more clinically actionable information. Both versions are complementary rather than mutually exclusive; understanding both mortality risk (FACED) and exacerbation risk (E-FACED) provides a more complete prognostic picture.

Comparison with the BSI (Bronchiectasis Severity Index)

The Bronchiectasis Severity Index (BSI), developed by Chalmers and colleagues from a UK-based cohort and published in 2014, represents the other major validated severity score in bronchiectasis. Both FACED and BSI were published in the same year and have been independently validated across multiple populations, making direct comparison informative for clinicians choosing between the tools.

The BSI is a more complex instrument incorporating ten variables — including FEV1, hospital admissions, exacerbation frequency, age, body mass index, Pseudomonas colonisation, other organism colonisation, radiological severity, and dyspnoea — yielding a maximum score of 26 points. While this greater complexity allows the BSI to capture more dimensions of disease burden, it also requires more data points and is somewhat more time-consuming to calculate. The FACED score, with only five components and a maximum score of 7, offers the advantage of simplicity and clinical practicality, particularly in settings with limited access to detailed microbiological data or where rapid bedside assessment is needed.

Studies comparing the two scores have generally found comparable discrimination for mortality, with some analyzes suggesting the BSI may have modest advantages for predicting hospitalisations and health-related quality of life outcomes. Most major bronchiectasis clinical guidelines, including those from the European Respiratory Society and the British Thoracic Society, acknowledge both tools as valid options, and clinician familiarity and local data availability often guide the practical choice between them.

Global Application and Population Considerations

Although developed from a Spanish cohort, the FACED score has demonstrated robust performance across diverse global populations, lending confidence to its broad clinical applicability. Validation studies from Italy, the United Kingdom, South Korea, Greece, Turkey, and Australia have each confirmed the score’s ability to discriminate between patients with different mortality risk levels, with the three-category severity classification broadly maintained across these settings.

Some variation in absolute mortality rates across cohorts is expected, reflecting differences in healthcare access, background comorbidity prevalence, microbiological patterns, and management practices. For example, cohorts from settings with high rates of post-infectious bronchiectasis (following tuberculosis or other endemic infections) may show different baseline mortality profiles than cohorts from high-income countries where primary immunodeficiency or genetic conditions are more commonly identified as the underlying etiology. These population-level differences affect the absolute mortality estimates but generally preserve the relative risk stratification that makes the score clinically useful.

Ethnic background may also influence bronchiectasis phenotype and prognosis. Studies in East Asian populations have noted relatively high rates of Pseudomonas colonisation in some centers and different patterns of radiological distribution. The FACED score has performed acceptably in these populations, though clinicians should remain aware that locally derived cohort data, where available, may provide more precise absolute mortality estimates than those from the original Spanish derivation study.

Integrating FACED Score into Clinical Practice

The FACED score is most valuable when used as part of a structured approach to bronchiectasis management rather than as an isolated calculation. In clinical practice, it is typically calculated at the time of bronchiectasis diagnosis confirmation (usually after initial HRCT reporting and spirometric assessment) and then reassessed at regular intervals — typically annually or following significant clinical events such as a hospitalisation or lung function decline.

For patients with mild FACED scores (0-2), clinical management can reasonably focus on optimising airway clearance techniques, ensuring appropriate vaccination (influenza and pneumococcal), identifying and treating any treatable underlying cause, and educating patients on recognising exacerbation features. Follow-up intervals of six to twelve months may be appropriate for stable patients in this category.

Moderate FACED scores (3-4) should prompt more proactive assessment including regular sputum bacteriology, consideration of long-term macrolide therapy (with appropriate audiological monitoring and macrolide resistance risk assessment), and referral to a specialist bronchiectasis clinic if not already established. Pulmonary function trends should be monitored at least six-monthly.

Severe FACED scores (5-7) identify a high-risk group requiring comprehensive specialist management. This may include multidisciplinary team discussion, pulmonary rehabilitation referral, consideration of inhaled antibiotic therapy for Pseudomonas-colonised patients, nutritional assessment, and in appropriate candidates, exploration of advanced therapies. Patient and family discussions about prognosis and advance care planning are relevant for patients at the severe end of the spectrum, particularly those with rapidly progressive disease.

Limitations of the FACED Score

Like all clinical prediction models, the FACED score has important limitations that should inform its appropriate use. It was developed for prognostication rather than treatment selection, and a high score does not in itself mandate any specific intervention — rather, it identifies patients who warrant closer attention and more comprehensive assessment.

The score does not capture several factors known to influence bronchiectasis outcomes, including nutritional status, comorbidity burden, body mass index, prior hospitalisation frequency, microbiological colonisation with organisms other than Pseudomonas aeruginosa, and underlying etiology. Patients with primary immunodeficiency, for example, may have additional prognostic considerations not reflected in the FACED total. Similarly, patients with concurrent COPD or asthma may experience different disease trajectories than those suggested by the FACED score alone.

The original cohort was predominantly composed of patients with idiopathic or post-infectious bronchiectasis and was recruited from specialist centers, which may limit generalisability to unselected community-based populations. Patients with milder disease managed exclusively in primary care may not fully reflect the characteristics of the derivation cohort.

Additionally, the score uses a single time-point measurement of FEV1 without accounting for the rate of lung function decline, which is itself a prognostically important variable. Patients with stable FEV1 values below 50% may have different outcomes from those experiencing rapid recent decline to the same absolute value.

Key Point: FACED Score is a Prognostic Tool, Not a Treatment Algorithm

The FACED score predicts mortality risk and helps stratify disease severity, but it does not prescribe specific treatments. Clinical decisions should integrate FACED score results with individualised assessment of symptoms, exacerbation history, comorbidities, underlying etiology, and patient preferences. Clinicians should use the score to guide monitoring intensity and prompt comprehensive assessment rather than as a mechanistic treatment trigger.

Aetiological Considerations in Bronchiectasis

Understanding the underlying cause of bronchiectasis is important for management, though the FACED score is applicable regardless of etiology. The most common identifiable causes include post-infectious bronchiectasis (following bacterial pneumonia, tuberculosis, pertussis, or measles), primary or secondary immunodeficiency, primary ciliary dyskinesia, allergic bronchopulmonary aspergillosis, connective tissue diseases, and inflammatory bowel disease. In a substantial proportion of patients — historically reported as 30 to 50% in many case series — no specific cause is identified despite thorough investigation, classifying them as having idiopathic bronchiectasis.

Aetiological diagnosis influences treatment in several important ways. Patients with identified immunodeficiency may benefit from immunoglobulin replacement therapy, which can dramatically reduce exacerbation frequency and disease progression. Primary ciliary dyskinesia requires specific management approaches and has implications for family screening. Allergic bronchopulmonary aspergillosis responds to antifungal and corticosteroid therapy. Because the FACED score does not capture etiology, all newly diagnosed patients should undergo systematic etiological investigation in parallel with prognostic assessment.

Exacerbation Recognition and Management

Bronchiectasis exacerbations are acute deteriorations in respiratory symptoms beyond normal day-to-day variation, typically characterized by increased sputum volume, change in sputum color or consistency, worsening dyspnoea, increased cough, systemic features of infection, or hemoptysis. Prompt recognition and treatment of exacerbations is critical because each event is associated with temporary quality-of-life impairment, lung function decline, and increased mortality risk — effects that accumulate with recurrent events over time.

The FACED score, while primarily a mortality predictor, provides useful context for exacerbation management decisions. Patients with high FACED scores who experience exacerbations may warrant more aggressive initial treatment, lower thresholds for hospitalisation, and more thorough post-exacerbation review. The E-FACED extension, which incorporates recent exacerbation history, is particularly helpful for identifying patients at highest risk of future exacerbation events who might benefit from intensified preventive therapy.

Spirometry and Lung Function in Bronchiectasis

The FEV1 component of the FACED score requires accurate spirometric measurement performed according to internationally accepted standards. Spirometry should ideally be performed during clinical stability — at least four weeks after an exacerbation — to avoid acute deterioration effects on measurement. Pre-bronchodilator FEV1 as a percentage of the predicted value (derived from appropriate reference equations for the patient’s age, sex, and height) is the relevant measurement for FACED scoring.

Bronchiectasis typically produces an obstructive or mixed spirometric pattern, although some patients may have predominantly normal spirometry early in their disease course. A significant proportion of bronchiectasis patients also have concomitant COPD, which can independently contribute to airflow obstruction and complicate interpretation of spirometric findings. In patients with severe obstruction who are unable to perform reproducible spirometry, the FEV1 component of the FACED score should be assigned based on the best achievable measurement, with appropriate notation of technical limitations.

Radiological Assessment for FACED Scoring

Accurate counting of affected lung lobes on HRCT is essential for the extension component of the FACED score. Standard lobe counting considers five lobes: the right upper lobe, right middle lobe, right lower lobe, left upper lobe (including the lingula), and left lower lobe. A lobe is typically considered affected if bronchiectatic changes are visible in any segment within it, regardless of the number of affected segments or the severity of changes.

HRCT remains the gold standard for bronchiectasis diagnosis and extent assessment. It should ideally be performed during clinical stability and without respiratory infection to minimise the confounding effects of mucus plugging and inflammatory exudate on lobe involvement assessment. When HRCT has been performed during an exacerbation, repeat imaging during stable disease is recommended before using the extension findings for FACED scoring.

The assessment of lobe involvement can sometimes be challenging in patients with bilateral lower lobe predominant disease, complex anatomy, or extensive consolidation. When uncertain about lobe involvement, consultation with an experienced thoracic radiologist is advisable to ensure accurate FACED extension scoring.

Key Point: Imaging Should Be Done During Clinical Stability

For accurate FACED scoring, HRCT should ideally be performed and interpreted during clinical stability, at least four to six weeks after an acute exacerbation. Exacerbation-related consolidation and mucus plugging can artificially increase the apparent extent of radiological involvement, leading to overestimation of the extension score and inflated total FACED scores that do not reflect the patient’s true stable-state disease burden.

Pseudomonas Aeruginosa: Clinical Significance in Bronchiectasis

Chronic bronchial colonisation with Pseudomonas aeruginosa represents one of the most clinically significant microbiological findings in bronchiectasis and is an independent determinant of prognosis across multiple scoring systems and outcome studies. This organism’s ability to form biofilms within the bronchial lumen renders it highly resistant to eradication by systemic antibiotics and conventional doses of inhaled antibiotics, contributing to persistent airway inflammation and progressive tissue damage.

Chronic colonisation is most commonly defined as the isolation of Pseudomonas aeruginosa from respiratory specimens on three or more separate occasions, at least one month apart, over a twelve-month period. A single positive culture in a patient who has not previously had Pseudomonas detected may reflect either transient acquisition or early colonisation, and some guidelines recommend attempted eradication with systemic antibiotics at this stage, before established biofilm formation makes eradication less feasible.

The management of Pseudomonas-colonised bronchiectasis patients typically involves regular microbiological surveillance (three to six monthly sputum cultures), consideration of long-term inhaled antibiotic therapy (with aztreonam, colistin, or tobramycin formulations approved for bronchiectasis in various jurisdictions), and appropriate antibiotic selection for exacerbation treatment based on up-to-date susceptibility patterns. Intravenous antibiotic therapy may be required for exacerbations in patients with resistant Pseudomonas strains or those who fail to respond to oral therapy.

FACED Score in Research and Clinical Trials

Beyond individual patient management, the FACED score has become an important tool in bronchiectasis clinical research. It provides a validated, reproducible method for characterising study populations and stratifying randomisation in clinical trials, ensuring balance between treatment groups with respect to disease severity. Several major bronchiectasis clinical trials have used FACED or E-FACED scores for participant characterisation or subgroup analysis, facilitating more meaningful cross-trial comparisons.

Regulatory agencies and guideline committees have increasingly incorporated FACED score thresholds into their frameworks for evaluating treatment eligibility and assessing the severity profile of enrolled populations in pharmaceutical trials. As the bronchiectasis therapeutic pipeline has expanded — particularly with the development of novel inhaled antibiotics and anti-inflammatory agents — validated prognostic tools like FACED have become essential instruments for trial design and regulatory submission.

Monitoring and Reassessment Over Time

The FACED score is not static; it should be reassessed periodically to capture disease evolution and treatment response. Most bronchiectasis experts recommend annual reassessment during routine clinic visits, with additional reassessment following significant clinical events such as hospitalisation for an exacerbation, detection of a new colonising organism, or lung function decline of more than 200 mL or 12% in FEV1.

Changes in FACED score over time carry prognostic significance. An increase in score (worsening severity category) should prompt review and intensification of management, investigation for new treatable factors, and consideration of the patient’s overall illness trajectory. Conversely, improvement in the FACED score — for example, following successful Pseudomonas eradication — provides objective evidence of treatment benefit and may support continuation of intensive therapeutic approaches.

Clinicians should document FACED score calculations and the data used for each component, creating an auditable longitudinal record of disease severity assessment that supports consistent care across providers and settings.

Frequently Asked Questions

What does FACED stand for?

FACED is an acronym derived from the five clinical variables that make up the scoring system: F for FEV1 (forced expiratory volume in one second as a percentage of predicted), A for Age, C for Chronic Pseudomonas aeruginosa colonisation, E for Extension (number of lung lobes affected on CT), and D for Dyspnoea severity measured on the modified MRC scale. The acronym also serves as a useful mnemonic for clinicians assessing bronchiectasis prognosis.

What is the maximum possible FACED score?

The maximum possible FACED score is 7 points. This occurs when a patient scores the maximum on every component: 2 points for FEV1 below 50% predicted, 2 points for age 70 years or older, 1 point for chronic Pseudomonas aeruginosa colonisation, 1 point for more than two lung lobes affected on CT, and 1 point for mMRC dyspnoea grade 2 or higher. A score of 7 places the patient in the severe category with significantly elevated five-year mortality risk.

How is the FACED score different from the E-FACED score?

The E-FACED score is an extension of the original FACED score that adds one additional variable: exacerbation history in the preceding year. A history of one or more exacerbations in the previous twelve months adds 2 points, raising the maximum possible score from 7 (FACED) to 9 (E-FACED). The E-FACED score was found to predict future exacerbation risk more accurately than the original FACED score, while both perform similarly for mortality prediction. Clinicians may use either or both, depending on their primary clinical question.

What FEV1 threshold is used in the FACED score?

The FACED score uses a threshold of 50% of predicted FEV1. Patients with an FEV1 below 50% of their predicted value score 2 points, while those with an FEV1 at or above 50% score 0 points. This measurement should be taken from spirometry performed during clinical stability, using pre-bronchodilator values and age-, sex-, and height-appropriate reference equations. Spirometry performed during or immediately after an acute exacerbation may not accurately reflect the patient’s stable-state lung function.

What age cut-point does the FACED score use?

The FACED score uses 70 years as the age threshold. Patients aged 70 years or older score 2 points for the age component, while younger patients score 0 points. This cut-point was determined empirically from the original derivation cohort and reflects the clinical observation that the impact of age on bronchiectasis mortality becomes substantially more pronounced after the seventh decade, when physiological reserve is more substantially reduced and comorbidity burden is typically higher.

How is chronic Pseudomonas aeruginosa colonisation defined for FACED scoring purposes?

Chronic Pseudomonas aeruginosa colonisation is typically defined as the isolation of this organism from respiratory specimens (usually spontaneous or induced sputum) on three or more separate occasions, at least one month apart, over a twelve-month period. A single positive culture or intermittent detection does not meet the definition of chronic colonisation. Microbiological confirmation should use validated culture techniques, and the relevant organism is specifically Pseudomonas aeruginosa — colonisation with other organisms does not contribute to this component.

How should lung lobe involvement be counted for the FACED extension component?

Lung lobe involvement should be assessed on high-resolution CT (HRCT) of the thorax, counting the five standard lung lobes: right upper, right middle, right lower, left upper (including lingula), and left lower. A lobe is counted as involved if bronchiectatic changes are present in any segment within it, regardless of severity or the number of affected segments. More than two lobes affected scores 1 point. This assessment should ideally use CT imaging obtained during clinical stability, as exacerbation-related changes can artifactually increase apparent lobe involvement.

What mMRC dyspnoea grade triggers a FACED point?

An mMRC (modified Medical Research Council) dyspnoea grade of 2 or higher scores 1 point in the FACED system. Grade 2 corresponds to walking slower than peers on level ground due to breathlessness, or needing to stop for breath when walking at one’s own pace. Grades 3 and 4 represent more severe impairment (stopping frequently on level ground, or unable to leave home due to breathlessness) and also score 1 point. Patients with grade 0 (breathless only with strenuous exercise) or grade 1 (short of breath on hills or hurrying) score 0 points for the dyspnoea component.

What is the five-year mortality rate associated with each FACED severity category?

Based on the original derivation and validation cohorts from the 2014 Martinez-Garcia study, five-year all-cause mortality rates were approximately 3 to 4% for mild bronchiectasis (score 0-2), around 15 to 20% for moderate bronchiectasis (score 3-4), and exceeding 50% in some analyzes for severe bronchiectasis (score 5-7). These figures should be interpreted with caution, as absolute mortality rates vary across populations and healthcare settings. Local cohort data, where available, may provide more accurate population-specific estimates.

Has the FACED score been validated outside of Spain?

Yes, the FACED score has been independently validated across multiple countries and healthcare systems, including cohorts from Italy, the United Kingdom, South Korea, Greece, Turkey, and Australia, among others. These validation studies have generally confirmed the score’s ability to stratify mortality risk across the three severity categories, though absolute mortality rates differ between cohorts, reflecting differences in healthcare access, comorbidity burden, management practices, and underlying disease etiologies. The broad cross-population validation provides confidence in the FACED score’s applicability to diverse patient groups.

Can the FACED score be used for cystic fibrosis bronchiectasis?

No, the FACED score was developed and validated exclusively in patients with non-cystic fibrosis bronchiectasis. Cystic fibrosis is a distinct genetic condition with a different natural history, pathophysiology, and treatment approach, and its prognosis is determined by different clinical factors. Validated prognostic models specifically developed for cystic fibrosis populations should be used for patients with CF. The FACED score should be applied only to adults with confirmed non-CF bronchiectasis.

Is the FACED score relevant for paediatric patients with bronchiectasis?

The FACED score was derived from and validated in adult patient cohorts and has not been validated in paediatric populations. Bronchiectasis in children has different etiological distributions, natural history, and prognostic determinants compared to adult bronchiectasis, and the FACED variables — particularly the age threshold and the mMRC dyspnoea scale — are not directly applicable to the paediatric context. Clinicians caring for children with bronchiectasis should use age-appropriate tools and consult paediatric respiratory specialists for prognostic guidance.

How often should the FACED score be recalculated?

Most bronchiectasis specialists recommend reassessing the FACED score at least annually during routine clinic reviews, using contemporaneous spirometry, updated CT data (where repeat imaging has been performed), and current clinical status. Additional reassessment should be triggered by significant clinical events, including hospitalisation for an exacerbation, identification of a new colonising organism, a clinically meaningful decline in lung function, or a change in dyspnoea grade. Documenting FACED scores longitudinally helps track disease trajectory and treatment response over time.

Does a high FACED score mean a patient will die within five years?

No, the FACED score predicts the probability of mortality within a five-year period at a population level — it does not determine the outcome for any individual patient. A patient with a severe FACED score (5-7) has a substantially elevated statistical risk of five-year mortality compared to a patient with a mild score, but individual outcomes vary considerably based on many factors not captured by the score, including comorbidities, response to treatment, exacerbation frequency, nutritional status, and social factors. The score should inform clinical decision-making and risk communication, not serve as a deterministic prediction for individuals.

Can the FACED score improve with treatment?

Yes, the FACED score can improve over time if treatable components are successfully addressed. For example, successful eradication of Pseudomonas aeruginosa colonisation would remove the 1-point contribution of the chronic colonisation component. Improvement in dyspnoea grade following pulmonary rehabilitation or optimization of inhaled therapy could similarly reduce the dyspnoea component score. The FEV1 and age components are less modifiable, though effective long-term management may slow the rate of lung function decline. Serial FACED reassessment can therefore provide an objective measure of treatment response over time.

How does the FACED score compare to the Bronchiectasis Severity Index (BSI)?

Both FACED and BSI are validated prognostic tools for non-CF bronchiectasis, developed independently in Spanish and UK cohorts respectively and published in the same year. The FACED score (5 variables, maximum 7 points) is simpler and quicker to calculate, while the BSI (10 variables, maximum 26 points) is more complex but may capture more dimensions of disease burden. Comparative studies generally show similar discrimination for mortality prediction. The BSI may have modest advantages for predicting hospitalisations and quality of life. Clinician preference, local data availability, and the specific clinical question often guide the choice between them.

What spirometry protocol is recommended for the FEV1 component?

Spirometry for the FEV1 component of the FACED score should be performed according to American Thoracic Society (ATS) and European Respiratory Society (ERS) technical standards, including at least three acceptable and reproducible manoeuvres, with the two highest FEV1 values within 150 mL of each other. Pre-bronchodilator FEV1 as a percentage of the predicted value (using appropriate reference equations for age, sex, and height — such as GLI 2012 reference values) is the relevant parameter. Testing should be performed during clinical stability, at least four weeks after an acute exacerbation.

Are there other organisms besides Pseudomonas that affect bronchiectasis prognosis?

Yes, several other organisms are associated with adverse outcomes in bronchiectasis, though the FACED score specifically considers only Pseudomonas aeruginosa. Methicillin-resistant Staphylococcus aureus (MRSA), Stenotrophomonas maltophilia, and Achromobacter xylosoxidans are all associated with more severe disease and treatment challenges. Non-tuberculous mycobacteria (NTM) represent a growing diagnostic challenge with distinct management requirements. While these organisms are not captured in the FACED score, their presence should inform overall clinical management decisions and may justify consideration of the more comprehensive BSI, which includes a broader organism category.

What does the FACED score not capture that clinicians should also consider?

The FACED score does not capture several clinically important factors, including exacerbation frequency (addressed by E-FACED), prior hospitalisations, nutritional status and body mass index, non-Pseudomonas bacterial colonisation, non-tuberculous mycobacterial infection, underlying etiology (which may guide specific therapies), comorbidities such as COPD or cardiac disease, rate of lung function decline, health-related quality of life measures, and socioeconomic factors affecting healthcare access. A comprehensive bronchiectasis assessment integrates the FACED score with these additional clinical dimensions rather than relying on it as the sole prognostic instrument.

Is special equipment needed to calculate the FACED score?

Calculation of the FACED score requires spirometry (for FEV1% predicted), high-resolution CT thorax (for lobe counting), and sputum microbiology results (for Pseudomonas colonisation status), in addition to patient age and clinician-assessed mMRC dyspnoea grade. While spirometry and CT are standard investigations in any respiratory clinic, they may not be immediately available in all healthcare settings. In resource-limited environments, some components may need to be estimated or deferred, which should be clearly documented when presenting the FACED score alongside the clinical assessment.

Can the FACED score guide antibiotic prescribing for exacerbations?

The FACED score does not directly prescribe specific antibiotics for exacerbation treatment — antibiotic selection should always be guided primarily by available sputum microbiology and local susceptibility data. However, the score provides important prognostic context: patients with high FACED scores experiencing an exacerbation may warrant more aggressive initial treatment (such as intravenous antibiotics over oral therapy), lower thresholds for hospitalisation, and more prompt specialist review. The score contextualises the clinical severity of the exacerbation episode rather than determining the specific antimicrobial choice.

Is the FACED score applicable to newly diagnosed patients without full microbiological history?

The FACED score can be applied to newly diagnosed patients, though the chronic Pseudomonas colonisation component requires at least twelve months of microbiological follow-up to assess reliably. For newly diagnosed patients without sufficient sputum culture history, this component may need to be scored as 0 (not chronically colonised) unless there is a clear prior history of repeated Pseudomonas isolation. Clinicians should acknowledge this limitation when applying the FACED score to patients early in their disease course, and plan serial reassessment as longitudinal microbiological data accumulates.

Are there guideline recommendations specifically linked to FACED score categories?

Major international bronchiectasis guidelines, including those from the European Respiratory Society (2017) and the British Thoracic Society, recommend the use of validated severity scores such as FACED or BSI in routine clinical practice for disease staging and management planning. While specific treatment protocols are not universally tied to FACED score thresholds, the score informs the intensity of monitoring and the appropriateness of long-term therapies such as inhaled antibiotics or macrolide prophylaxis. Local and national guidelines may provide more specific management algorithms linked to severity categories.

What is the relationship between the FACED score and pulmonary rehabilitation?

Pulmonary rehabilitation — comprising structured exercise training and patient education — is beneficial across all severities of bronchiectasis and can improve exercise capacity, dyspnoea, and quality of life. Patients with higher FACED scores (particularly those with mMRC dyspnoea grades of 2 or higher) may have particularly significant functional impairment and stand to benefit substantially from rehabilitation programmes. The FACED score can therefore help identify patients for whom pulmonary rehabilitation referral should be prioritised, though the intervention itself is not contraindicated at any score level.

How should clinicians communicate FACED score results to patients?

FACED score results should be communicated to patients in accessible language, framing the score as an assessment of disease severity and long-term outlook rather than a precise individual prediction. Patients should understand that the score reflects average outcomes across populations with similar characteristics and that their individual prognosis depends on many additional factors. Emphasising modifiable elements — such as the potential impact of airway clearance adherence, vaccination, and exacerbation prevention on long-term outcomes — can help patients feel empowered rather than anxious about their score. Shared decision-making based on prognostic information supports patient engagement in their own management.

Where can I find more information about bronchiectasis management guidelines?

Comprehensive bronchiectasis management guidelines are available from the European Respiratory Society (ERS), which published its first dedicated bronchiectasis guideline in 2017, and from the British Thoracic Society (BTS), which has provided updated guidance covering diagnosis, investigation, and management. The European Multicenter Bronchiectasis Audit and Research Collaboration (EMBARC) also publishes consensus documents and audit data. National respiratory societies in multiple countries have adapted these international frameworks to local practice contexts. All these organizations maintain publicly accessible websites where current guidelines and educational resources can be accessed.

Conclusion

The FACED score provides clinicians with a practical, validated, and internationally applicable tool for stratifying the severity and predicting five-year mortality risk in adults with non-cystic fibrosis bronchiectasis. By combining five readily obtainable clinical parameters — FEV1 percentage of predicted, patient age, Pseudomonas aeruginosa colonisation status, radiological extent of disease, and mMRC dyspnoea grade — it achieves meaningful risk stratification in a format that can be applied in routine clinical practice without specialist statistical software or extensive data collection.

Used appropriately, the FACED score complements rather than replaces comprehensive clinical assessment. It informs monitoring intensity, guides management escalation decisions, facilitates meaningful prognosis discussions with patients, and provides a standardised language for describing disease severity in research and audit contexts. Clinicians are encouraged to reassess the score regularly, document it as part of the longitudinal clinical record, and integrate it with the full clinical picture — including exacerbation history, comorbidities, underlying etiology, and patient-reported outcomes — to deliver individualised, evidence-based bronchiectasis care.

As the therapeutic landscape for bronchiectasis continues to evolve with new inhaled antibiotics, anti-inflammatory agents, and biological therapies entering development, validated prognostic tools like the FACED score will play an increasingly important role in identifying appropriate candidates for novel treatments, designing rigorous clinical trials, and demonstrating treatment benefit across meaningful patient subgroups. For patients and clinicians alike, the FACED score represents an important step toward the systematic, stratified approach to bronchiectasis management that this underserved condition has long required.